Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Sep 8;17:638. doi: 10.1186/s12885-017-3639-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2017

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 2 — PTEN mutations sensitize endometrial cancer cells to PARP inhibitors. In a clonogenic assay at day 5 (D5), the sensitivity to olaparib is higher for the PTEN mutated cell lines, Ishikawa and AN3CA compared to the PTEN wild-type cell lines, HEC-50 and HEC-B1 (a). BMN-673 shows a higher efficiency of inhibitory activity than olaparib in all cell lines (b). The transfected shPTEN cell lines were more sensitive to both olaparib and BMN-637 compared to their wild type PTEN counterparts c and d which confirms the higher sensitivity to PARP-inhibitors when PTEN is mutated